Greden J.F. et al. (2019). J Psychiatr Res – GUIDED trial results on pharmacogenomic testing vs standard care.
Oslin D.W. et al. (2022). JAMA – PRIME Care RCT on pharmacogenomic-guided treatment in veterans.
Zhang K. et al. (2023). BMC Psychiatry – Meta-analysis of 11 RCTs of pharmacogenetics in depression.
CPIC (2023) – Guidelines for CYP2D6/CYP2C19 genotypes and SSRI dosing.
Hicks J.K. et al. (2015). Clin Pharmacol Ther – FDA and CPIC guideline annotations for citalopram and CYP2C19.
Ji Y. et al. (2010). Pharmacogenomics J – CYP2D6 genotype and antidepressant metabolism recommendations.
Porcelli S. et al. (2012). J Clin Psychiatry – Meta-analysis on 5-HTTLPR and antidepressant response in ethnicity subgroups.
Fawver J. et al. (2020). Brain Behav – COMT Val158Met genotype and differential response to bupropion treatment.
Peters F.T. et al. (2018). Am J Psychiatry – CYP2C19 genotype effects on escitalopram metabolism and therapy switching (therapeutic failure).
Insinga R.P. et al. (2022). Psychiatry Res – Combinatorial pharmacogenomics vs single-gene prediction of SSRI levels.
